STRATA Skin Sciences announced on September 30, 2025, the publication of a new peer-reviewed study in Lasers in Medical Science. The study reinforces the company's commitment to personalized medicine by demonstrating the enhanced efficacy of its XTRAC 308nm Excimer Laser.
The research, titled 'Clinical efficacy of 308 nm excimer laser irradiation combined with 0.1% tacrolimus ointment in the treatment of plaque-type psoriasis,' involved 100 adult patients. It concluded that combining XTRAC treatment with 0.1% tacrolimus ointment significantly improved outcomes compared to topical monotherapy alone.
This latest clinical validation adds to the extensive body of evidence supporting Excimer therapy and strengthens STRATA's case for expanded reimbursement. The study highlights the XTRAC system's ability to integrate seamlessly with topical and systemic therapies, offering flexible and safe treatment options for plaque-type psoriasis patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.